Zanidatamab Gets Priority Review for HER2-Amplified Biliary Tract Cancer
Zanidatamab is a HER2-targeted bispecific antibody that can simultaneously bind 2 non-overlapping epitopes of the HER2 receptor.
Source: empr.com
Page 5 - Priority Review News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Priority Review Today - Breaking & Trending Today
Dupilumab Improves Outcomes in COPD With Type 2 Inflammation
New trial confirmed safety and efficacy of a subcutaneous add-on therapy for uncontrolled COPD.
Source: medscape.com
Sanofi's Sarclisa Granted FDA Priority Review For Transplant-Ineligible Multiple Myeloma Treatment
(RTTNews) - Sanofi - Aventis Groupe said that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics Li...
Source: businessinsider.com
Sarclisa Accepts for FDA Priority Review for the Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
The U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for the investigational use of Sarclisa in combination with bortezomib,...
Source: marketscreener.com
Sanofi: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase
Source: finanznachrichten.de